The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase II trial of the CDK4 inhibitor PD0332991 in patients with advanced CDK4-amplified liposarcoma.
Mark Andrew Dickson
Consultant or Advisory Role - Pfizer
William D. Tap
No relevant relationships to disclose
Mary Louise Keohan
No relevant relationships to disclose
Sandra P. D'Angelo
No relevant relationships to disclose
Mrinal M. Gounder
No relevant relationships to disclose
Ping Chi
No relevant relationships to disclose
Cristina R. Antonescu
No relevant relationships to disclose
Jonathan Landa
No relevant relationships to disclose
Li-Xuan Qin
No relevant relationships to disclose
Dustin D. Rathbone
No relevant relationships to disclose
Yelena Ustoyev
No relevant relationships to disclose
Aimee Marie Crago
No relevant relationships to disclose
Samuel Singer
Consultant or Advisory Role - Pfizer
Gary K. Schwartz
Consultant or Advisory Role - Pfizer
Mercedes M. Condy
No relevant relationships to disclose